Caduceus Showcases New Alzheimer’s Blood Test Technology at Healthcare+ Expo 2025

Taipei, December 2025 — Caduceus participated in the Healthcare+ Expo 2025 from December 4 to 7, 2025, held at Taipei Nangang Exhibition Center, Hall 1, presenting its latest Alzheimer’s disease (AD) blood biomarker testing technology. This innovative, simple, fast, and highly sensitive test attracted strong interest from hospitals, health screening centers, and long-term care organizations.

Caduceus’ AD blood test analyzes key biomarkers through a standard blood draw, supporting early screening, mild cognitive impairment (MCI) assessment, and ongoing disease monitoring. It offers a more accessible and clinically friendly tool for managing neurodegenerative diseases in an aging society.

In addition to the AD test, the company also showcased its digital health management platform and rapid diagnostic technologies. By integrating digital solutions with precision testing, Caduceus aims to enhance clinical efficiency and promote the development of preventive healthcare. The exhibition further drew attention from buyers in Southeast Asia, the Middle East, and Europe, highlighting the company’s growing international potential in the precision medicine field.

Caduceus will continue investing in early detection and smart healthcare technologies, working closely with medical and long-term care partners to build a more comprehensive and future-oriented health management ecosystem.